Literature DB >> 29371155

SOX2: Not always eye malformations. Severe genital but no major ocular anomalies in a female patient with the recurrent c.70del20 variant.

Edoardo Errichiello1, Cristina Gorgone2, Loretta Giuliano3, Barbara Iadarola4, Emanuela Cosentino4, Marzia Rossato4, Nehir Edibe Kurtas5, Massimo Delledonne4, Teresa Mattina6, Orsetta Zuffardi5.   

Abstract

SOX2 variants have been identified in multiple patients with severe ocular anomalies and pituitary dysfunction, in addition to various systemic features. We investigated a 26-year-old female patient suffering from spastic paraparesis, hypoplasia of corpus callosum, hypogonadotropic hypogonadism (HH) and intellectual disability, who was monitored for over 20 years, allowing a detailed genotype-phenotype correlation along time. Whole exome sequencing on the patient and her relatives identified a de novo SOX2 c.70del20 variant, which has been frequently reported in individuals with SOX2-related anophthalmia. Importantly, our patient lacked major ocular phenotype but showed vaginal agenesis, a feature never reported before. Although the involvement of male urogenital tract (cryptorchidism, hypospadias, small penis), is a well known consequence of SOX2 variants, their effect on the female genitalia has never been properly addressed, even considering the paradoxical female excess of SOX2 cases in the literature. Our findings emphasize the importance of testing for SOX2 variants in individuals with HH and genital anomalies even though anophthalmia or microphthalmia are not observed. Moreover, our case strengthens the role of SOX2 as a master regulator of female gonadal differentiation, as widely demonstrated for other SOX genes related to 46, XX sex reversal, such as SOX3 and SOX9.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Anophthalmia/microphthalmia; Hypogonadotropic hypogonadism; Hypoplastic uterus; SOX2; Undetectable ovaries; Vaginal agenesis

Mesh:

Substances:

Year:  2018        PMID: 29371155     DOI: 10.1016/j.ejmg.2018.01.011

Source DB:  PubMed          Journal:  Eur J Med Genet        ISSN: 1769-7212            Impact factor:   2.708


  5 in total

Review 1.  Genetics of anophthalmia and microphthalmia. Part 2: Syndromes associated with anophthalmia-microphthalmia.

Authors:  Anne Slavotinek
Journal:  Hum Genet       Date:  2018-10-30       Impact factor: 4.132

2.  Clinical diagnosis of presumed SOX2 gonadosomatic mosaicism.

Authors:  Malena Daich Varela; Robert B Hufnagel; Bin Guan; Delphine Blain; Julie C Sapp; Andrea L Gropman; Ramakrishna Alur; Jennifer J Johnston; Leslie G Biesecker; Brian P Brooks
Journal:  Ophthalmic Genet       Date:  2021-03-15       Impact factor: 1.274

3.  Review of 37 patients with SOX2 pathogenic variants collected by the Anophthalmia/Microphthalmia Clinical Registry and DNA research study.

Authors:  Louise Amlie-Wolf; Tanya Bardakjian; Sarina M Kopinsky; Linda M Reis; Elena V Semina; Adele Schneider
Journal:  Am J Med Genet A       Date:  2021-09-25       Impact factor: 2.578

4.  De Novo Missense Variants in FBXW11 Cause Diverse Developmental Phenotypes Including Brain, Eye, and Digit Anomalies.

Authors:  Richard J Holt; Rodrigo M Young; Berta Crespo; Fabiola Ceroni; Cynthia J Curry; Emanuele Bellacchio; Dorine A Bax; Andrea Ciolfi; Marleen Simon; Christina R Fagerberg; Ellen van Binsbergen; Alessandro De Luca; Luigi Memo; William B Dobyns; Alaa Afif Mohammed; Samuel J H Clokie; Celia Zazo Seco; Yong-Hui Jiang; Kristina P Sørensen; Helle Andersen; Jennifer Sullivan; Zöe Powis; Anna Chassevent; Constance Smith-Hicks; Slavé Petrovski; Thalia Antoniadi; Vandana Shashi; Bruce D Gelb; Stephen W Wilson; Dianne Gerrelli; Marco Tartaglia; Nicolas Chassaing; Patrick Calvas; Nicola K Ragge
Journal:  Am J Hum Genet       Date:  2019-08-08       Impact factor: 11.025

Review 5.  Congenital Hypopituitarism During the Neonatal Period: Epidemiology, Pathogenesis, Therapeutic Options, and Outcome.

Authors:  Laura Bosch I Ara; Harshini Katugampola; Mehul T Dattani
Journal:  Front Pediatr       Date:  2021-02-02       Impact factor: 3.418

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.